{"schema_version":"secwatch.filing_event.v1","accession":"0001628945-23-000002","form_type":"8-K","ticker":null,"cik":"0001628945","company_name":"Cue Health Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.921333+00:00","generated_at":"2026-06-20T19:39:31.965109+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cue Health reduces workforce by 26% (388 employees) in cost reduction plan","bullets":["Workforce reduction of 388 employees (~26% of global staff) announced Jan 5, 2023.","Estimated cash restructuring charges of $6.0M to $8.0M; non-cash equity charges ~$0.2M.","CEO Ayub Khattak cites pandemic demand decline and uncertain regulatory timelines for new products.","Pipeline progress noted: Flu+COVID test, RSV, strep, chlamydia/gonorrhea, Mpox submissions underway.","Severance includes min 9 weeks pay, PTO payout, healthcare through March 2023, partial equity acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001628945-23-000002","json":"https://secwatch.observer/filing/0001628945-23-000002.json","markdown":"https://secwatch.observer/filing/0001628945-23-000002.md","text":"https://secwatch.observer/filing/0001628945-23-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628945/000162894523000002/0001628945-23-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628945/000162894523000002/hlth-20230105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:39:31.965109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04157b15cd8b256909471c8ea1f0aaeb60c02fdb","claim":"Cue Health Inc. announced a restructuring with charges of approximately $6.0 million to $8.0 million (388 employees, which constitutes a reduction of approximately 26% in the Company’s global workforce).","evidence_excerpt":"The CRP will include a reduction in the Company’s employee base by 388 employees, which constitutes a reduction of approximately 26% in the Company’s global workforce. In connection with the CRP, the Company estimates that it will record an aggregate restructuring charge related to one-time termination benefits in the range of approximately $6.0 million to $8.0 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628945/000162894523000002/0001628945-23-000002-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $6.0 million to $8.0 million"},{"label":"Headcount","value":"388 employees, which constitutes a reduction of approximately 26% in the Company’s global workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}